Lumos Pharma Inc expected to post a loss of $1.03 a share - Earnings Preview

Lumos Pharma

03/08/2021 16:25

* Lumos Pharma Inc  LUMO.OQ   LUMO.O  is expected to show a fall
in quarterly revenue when it reports results on August 5. 
​* Refinitiv's mean analyst estimate for Lumos Pharma Inc is for
a loss of $1.03 per share. For the same quarter last year, the
company reported a loss of 65 cents per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Lumos Pharma
Inc is $29.5​, about 71.5% above​ its last closing price
of $8.41. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.88       -0.87      -1.04     Missed  -19
 Dec. 31 2020  -0.86       -0.86      -0.31     Beat    64
 Sep. 30 2020  -0.66       -0.64      0.21      Beat    132.6​
 Jun. 30 2020  -0.72       -0.71      -0.65     Beat    8.9
 Mar.          -0.83​      -0.82      -0.14     Beat    83​
 31​ 2020​                                              
 Dec. 31 2019  -2.52       -2.52      -1.98     Beat    21.4​
 Sep. 30 2019  -2.43       -2.43      -2.43     Met     0
 Jun. 30 2019              -2.61      -2.43     Beat    6.9
 This summary was machine generated August 3 at 15:25 GMT.  All
figures in US dollars unless otherwise stated